P
Paul Komenda
Researcher at University of Manitoba
Publications - 170
Citations - 4550
Paul Komenda is an academic researcher from University of Manitoba. The author has contributed to research in topics: Kidney disease & Dialysis. The author has an hindex of 31, co-authored 159 publications receiving 3366 citations. Previous affiliations of Paul Komenda include University of Winnipeg & Seven Oaks General Hospital.
Papers
More filters
Journal ArticleDOI
Dialysis initiation, modality choice, access, and prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Christopher T. Chan,Peter J. Blankestijn,Laura M. Dember,Maurizio Gallieni,David Harris,Charmaine E. Lok,Rajnish Mehrotra,Paul E. Stevens,Angela Yee-Moon Wang,Michael Cheung,David C. Wheeler,Wolfgang C. Winkelmayer,Carol A. Pollock,Ali K. Abu-Alfa,Joanne M. Bargman,Anthony J. Bleyer,Edwina A. Brown,Andrew Davenport,Simon J. Davies,Frederic O. Finkelstein,Jennifer E. Flythe,Eric Goffin,Thomas A. Golper,Rafael Gomez,Takayuki Hamano,Manfred Hecking,Olof Heimbürger,Barnaby Hole,Daljit Hothi,T. Alp Ikizler,Yoshitaka Isaka,Kunitoshi Iseki,Vivekanand Jha,Hideki Kawanishi,Peter G. Kerr,Paul Komenda,Csaba P. Kovesdy,Ed Lacson,Maurice Laville,Jung Pyo Lee,Edgar V. Lerma,Nathan W. Levin,Monika Lichodziejewska-Niemierko,Adrian Liew,Elizabeth Lindley,Robert S. Lockridge,Magdalena Madero,Ziad A. Massy,Linda M. McCann,Klemens B. Meyer,Rachael L. Morton,Annie Claire Nadeau-Fredette,Hirokazu Okada,José Pérez,Jeff Perl,Kevan R. Polkinghorne,Miguel C. Riella,Bruce M. Robinson,Michael V. Rocco,Steven J. Rosansky,Joris I. Rotmans,María Fernanda Slon Roblero,Navdeep Tangri,Marcello Tonelli,Allison Tong,Yusuke Tsukamoto,Kriang Tungsanga,Tushar J. Vachharajani,Ismay van Loon,Suzanne Watnick,Daniel E. Weiner,Martin Wilkie,Elena Zakharova +72 more
TL;DR: The need to move away from a "one-size-fits-all" approach to dialysis and provide more individualized care that incorporates patient goals and preferences while still maintaining best practices for quality and safety is represented during the KDIGO conference.
Journal ArticleDOI
Non-invasive endothelial function testing and the risk of adverse outcomes: a systematic review and meta-analysis
Yang Xu,Rakesh C. Arora,Brett Hiebert,Blake Lerner,Andrea Szwajcer,Kerry McDonald,Claudio Rigatto,Paul Komenda,Manish M. Sood,Navdeep Tangri +9 more
TL;DR: A systematic review and meta-analysis was performed to determine whether brachial FMD and peripheral arterial tonometry (PAT) are independent risk factors for future cardiovascular events and mortality as discussed by the authors.
Journal ArticleDOI
Urinary, Plasma, and Serum Biomarkers' Utility for Predicting Acute Kidney Injury Associated With Cardiac Surgery in Adults: A Meta-analysis.
Julie Ho,Navdeep Tangri,Paul Komenda,Amit Kaushal,Manish M. Sood,Ranveer Brar,Kamal Gill,Simon M. Walker,Kerry Macdonald,Brett Hiebert,Rakesh C. Arora,Rakesh C. Arora,Claudio Rigatto +12 more
TL;DR: In adults, known urinary, plasma, and serum biomarkers of AKI possess modest discrimination at best when measured within 24 hours of cardiac surgery.
Journal ArticleDOI
Intensive Hemodialysis Associates with Improved Survival Compared with Conventional Hemodialysis
Gihad Nesrallah,Robert M. Lindsay,Meaghan S. Cuerden,Amit X. Garg,Amit X. Garg,Friedrich K. Port,Peter C. Austin,Louise Moist,Andreas Pierratos,Christopher T. Chan,Deborah Zimmerman,Robert S. Lockridge,Cécile Couchoud,Charles Chazot,Norma J. Ofsthun,Adeera Levin,Michael Copland,Mark Courtney,Andrew W. Steele,Philip A. McFarlane,Denis F. Geary,Robert P. Pauly,Paul Komenda,Rita S. Suri +23 more
TL;DR: There is a strong association between intensive home hemodialysis and improved survival, but whether this relationship is causal remains unknown.
Journal ArticleDOI
Cost-effectiveness of Primary Screening for CKD: A Systematic Review
Paul Komenda,Paul Komenda,Thomas W. Ferguson,Kerry Macdonald,Claudio Rigatto,Claudio Rigatto,Chris Koolage,Chris Koolage,Manish M. Sood,Navdeep Tangri,Navdeep Tangri +10 more
TL;DR: CKD screening may be cost-effective in populations with higher incidences of CKD, rapid rates of progression, and more effective drug therapy as well as patients with diabetes and hypertension.